Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland (P.A.M., K.T.H., R.A.M., H.T., N.P., S.F.).
Division of Vascular Surgery, Department of Surgery (Y.K., J.Y., N.J.L.), Stanford University School of Medicine, CA.
Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):e1-e9. doi: 10.1161/ATVBAHA.121.316854. Epub 2021 Nov 11.
Antibody blockade of the "do not eat me" signal CD47 (cluster of differentiation 47) enhances efferocytosis and reduces lesion size and necrotic core formation in murine atherosclerosis. TNF (Tumor necrosis factor)-α expression directly enhances expression, and elevated TNF-α is observed in the absence of the proefferocytosis receptor LRP1 (low-density lipoprotein receptor-related protein 1), a regulator of atherogenesis and inflammation. Thus, we tested the hypothesis that CD47 blockade requires the presence of macrophage LRP1 to enhance efferocytosis, temper TNF-α-dependent inflammation, and limit atherosclerosis. Approach and Results: Mice lacking systemic apoE (apoE), alone or in combination with the loss of macrophage LRP1 (double knockout), were fed a Western-type diet for 12 weeks while receiving anti-CD47 antibody (anti-CD47) or IgG every other day. In apoE mice, treatment with anti-CD47 reduced lesion size by 25.4%, decreased necrotic core area by 34.5%, and decreased the ratio of free:macrophage-associated apoptotic bodies by 47.6% compared with IgG controls (<0.05), confirming previous reports. Double knockout mice treated with anti-CD47 showed no differences in lesion size, necrotic core area, or the ratio of free:macrophage-associated apoptotic bodies compared with IgG controls. In vitro efferocytosis was 30% higher when apoE phagocytes were incubated with anti-CD47 compared with IgG controls (<0.05); however, anti-CD47 had no effect on efferocytosis in double knockout phagocytes. Analyses of mRNA and protein showed increased CD47 expression in anti-inflammatory IL (interleukin)-4 treated LRP1 macrophages compared with wild type, but no differences were observed in inflammatory lipopolysaccharide-treated macrophages.
The proefferocytosis receptor LRP1 in macrophages is necessary for anti-CD47 blockade to enhance efferocytosis, limit atherogenesis, and decrease necrotic core formation in the apoE model of atherosclerosis.
抗体阻断“不要吃我”信号 CD47(分化群 47)增强吞噬作用,并减少小鼠动脉粥样硬化中的病变大小和坏死核心形成。TNF(肿瘤坏死因子)-α表达直接增强 表达,并且在缺乏促吞噬受体 LRP1(低密度脂蛋白受体相关蛋白 1)的情况下观察到升高的 TNF-α,LRP1 是动脉粥样硬化形成和炎症的调节剂。因此,我们检验了这样一个假设,即 CD47 阻断需要巨噬细胞 LRP1 的存在来增强吞噬作用,调节 TNF-α依赖性炎症,并限制动脉粥样硬化。方法和结果:单独或与巨噬细胞 LRP1 缺失(双重缺失)组合的缺乏系统性 apoE(apoE)的小鼠在接受抗 CD47 抗体(抗 CD47)或 IgG 每隔一天治疗的情况下,喂食西方型饮食 12 周。在 apoE 小鼠中,与 IgG 对照相比,用抗 CD47 治疗使病变面积减少 25.4%,坏死核心面积减少 34.5%,自由体:巨噬细胞相关凋亡体的比值减少 47.6%(<0.05),证实了先前的报告。与 IgG 对照相比,用抗 CD47 治疗的双重缺失小鼠在病变大小、坏死核心面积或自由体:巨噬细胞相关凋亡体的比值方面没有差异。与 IgG 对照相比,apoE 吞噬细胞与抗 CD47 孵育时吞噬作用提高了 30%(<0.05);然而,抗 CD47 对双重缺失吞噬细胞的吞噬作用没有影响。mRNA 和蛋白质分析表明,与野生型相比,抗炎性 IL(白细胞介素)-4 处理的 LRP1 巨噬细胞中 CD47 表达增加,但在炎症性脂多糖处理的巨噬细胞中没有差异。结论:巨噬细胞中的促吞噬受体 LRP1 是抗 CD47 阻断增强吞噬作用、限制动脉粥样硬化形成和减少 apoE 动脉粥样硬化模型中坏死核心形成所必需的。